Advances in the treatment of chronic lymphocytic leukemia (CLL);Neuere entwicklungen in der therapie der chronisch lymphatischen leukamie (CLL)

Wiener Klinische Wochenschrift

Volumn 110, Issue 20, 1998, Pages 701-708

  Lechner, Klaus ^a   Jäger, Ulrich ^a   Geissler, Klaus ^a   Greinix, Hildegard ^a   Kalhs, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chronic lymphocytic leukemia; Fludarabine; Stem cell transplantation; Treatment

Indexed keywords

CHLORAMBUCIL; CLADRIBINE; FLUDARABINE; MONOCLONAL ANTIBODY; PREDNISONE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; HUMAN; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC;

EID: 0032582566     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Bay JO, Fouassier M, Beal D, Alcaraz L, Cure H, Chollet P, Plagne R, Travade P (1997) Autoimmune thrombocytopenia after six cycles of fludarabine phosphate in a patient with chronic lymphocytic leukemia. Hematol Cell Ther 39: 209-212
2. Bosch F, Perales M, Cobo F, Esteve J, Rafel M, López-Guillermo A, Ribera JM, Campo E, Montserrat E (1997) Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL). Blood 90: 530a
3. Braess J, Reich K, Willen S, Strutz F, Neumann C, Hiddemann W, Wörmann B (1997) Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL). Ann Hematol 75: 227-230
4. Byrd JC, Rai KR, Sausvillc EA, Grever MR (1998) Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. Semin Oncol 25: 65-74
5. Cheson BD (1995) Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13: 2431-2448
6. Cheson BD, Frame JN, Vena D, Quashu N, Sorensen JM (1998) Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 16, 2313-2320
7. Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T, Vegna ML, Guglielmi C, Mancini F, Giuliacci S, Sacchi A, Mandelli F, Foa R (1998) p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 91: 4342-4349
8. Delannoy A, Martiat P, Gala JL, Deneys V, Ferrant A, Scheiff JM, Michaux JL (1995) 2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL). Leukemia 9: 1130-1135
9. Delannoy A, Hanique G, Ferrant A (1993) 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Enal J Med 328: 812-814
10. DeNardo GL, Lewis JP, DeNardo SJ, O'Grady LF (1994) Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer 73: 1425-1432
11. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, Lepomer M, Jaubert J, Lepeu G, Dreyfus B, Bmet JL, Travade P, for the French Cooperative Group on Chronic Lymphocytic Leukemia (1998) Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 338: 1506-1514
12. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichter P (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85: 1580-1589
13. Dreger P, Schmitz N (1997) The role of stem cell transplantation in the treatment of chronic lymphocytic leukemia. Leukemia 11: S42-S45
14. Dyer MJS, Kelsey SM, Mackay HJ, Emmett E, Thornton P, Hale G, Waldmann H, Newland AC, Catovsky D (1997) In vivo 'purging' of residual disease in CLL with Campath-1H. Br J Haematol 97: 669-672
15. Esteve J, Villamor N, Colomer D, Bosch F, Lopez-Guillermo A, Rovira M, Urbano-Ispizua A, Sierra J, Carreras E, Montserrat E (1998) Hematopoietic stem cell transplantation in chronic lymphocytic leukemia: a report of 12 patients from a single institution. Ann Oncol 9: 167-172
16. Hallek M, Wanders L, Strohmeyer S, Emmerich B (1992) Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol 65: 1-5
17. Hansen MM, Andersen E, Birgens H, Christensen BE, Christensen TG, Geisler C, Meldgaard K, Pedersen D (1991) CHOP versus chlorambucil + prednisolone in chronic lymphocytic leukemia. Leukemia Lymphoma [Suppl] 97-100
18. Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B, Wyld PJ, Hiddemann W (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia The French Cooperative Group on CLL. Lancet 347: 1432-1438
19. Juliusson G, Christiansen I, Hansen MM, Johnson S, Kimby E, Elmhorn-Rosenborg A, Liliemark J (1996) Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 14: 2160-2166
20. Juliusson G, Elmhorn-Rosenborg A, Liliemark J (1992) Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 327: 1056-1061
21. Juliusson G, Liliemark J (1996) Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia. Ann Oncol 7: 373-379
22. Juliusson G, Liliemark J (1993) Complete remission of B-cell chronic lymphocytic leukaemia after oral cladribine. Lancet 341: 54-55
23. Keating MJ, Lerner S, Kantarjian H, Freireich EJ, O'Brien S (1995) The serum β2-microglobulin (β2M) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL). Blood 86: 606a
24. Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, Beran M, Freireich EJ (1993) Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81: 2878-2884
25. Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, Andersson BS, van Besien KW, Mehra RC, Giralt SA, Ippoliti C, Marshall M, Thomas MW, O'Brien S, Robertson LE, Deisseroth AB, Champlin RE (1994) Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 12: 748-758
26. Khouri IF, Przepiorka D, van Besien K, O'Brien S, Palmer JL, Lerner S, Mehra RC, Vriesendorp HM, Andersson BS, Giralt S, Körbling M, Keating MJ, Champlin RE (1997) Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol 97: 466-473
27. Lens D, Dyer MJS, Garcia-Marco JM, de Schouwer PJJC, Hamoudi RA, Jones D, Farahat N, Matutes E, Catovsky D (1997) p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis. Br J Haematol 99: 848-857
28. Leporrier M, Chevret S, Cazin B, Feugier P, Rapp MJ, Boudjerra N, Autrand C, Dreyfus B, Desablens B, Dighiero G, Travade Ph, Chastang Cl, Binet JL (1997) Randomized comparison of fludarabine, CAP and ChOP, in 695 previously untreated stage B and C chronic lymphocytic leukemia (CLL). Early stopping of the CAP accrual. Blood 90: 529a (Abstr)
29. Linassier C, Cahn JY, Desablens B, Senesébé L, Vilque JP, Witz F, Combe M, Luthier F, Deconninck E, Malivoir B, Colombat Ph (1997) First line high-dose chemotherapy with purged autologous bone marrow transplantation (ABMT) in advanced CLL (Binet stage B-C): Results of a prospective phase II study. Blood 90: 234a (Abstr)
30. List AF, Kummet TD, Adams JD, Chun HG (1990) Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate. Am J Med 89: 388-390
31. Maung ZT, Wood AC, Jackson GH, Turner GE, Appleton AL, Hamilton PJ (1994) Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol 88: 649-652
32. Michallet M, Archimbaud E, Bandini G, Rowlings PA, Dees HJ, Gahrton G, Montserrat E, Rozman C, Gratwohl A, Gale RP, for the European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry (1996) HLA-identical sibling hone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 124: 311-315
33. Milligan DW, Davies FE, Morgan GJ, Auer RL, Child JA, Ahsan G, Schey SA, Catovsky D, on behalf of the UK MRC Chronic Lymphocytic Leukaemia Working Group (1997) Autologous transplantation for younger patients with chronic lymphocytic leukaemia. Blood 90: 234a (Abstr)
34. Mitterbauer M, Hilgenfeld E, Wilfing A, Jäger U, Knauf WU (1997) Is there a place for 2-CDA in the treatment of B-CLL? Leukemia 11: 35-37
35. Montserrat E, Lopez-Lorenzo JL, Manso F, Martin A, Prieto E, Arias-Sampedro J, Fernandez MN, Oyarzabal FJ, Odriozola J, Alcala A, Garcia-Conde J, Guardia R, Bosch F (1996) Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. Leuk Lymphoma 21: 467-472
36. Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG, Hamon MD, Oscier DG, Hamblin TJ (1995) Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 91: 341-344
37. Nakhoul F, Green J, Abassi ZA, Carter A (1996) Tumor lysis syndrome induced by fludarabine monophosphate: a case report. Eur J Haematol 56: 254-255
38. O'Brien S, Kantarjian H, Beran M, Freireich E, Kornblau S, Koller C, Lerner S, Gilbreath J, Keating M (1996) Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL). Blood 88: 480a (Abstr)
39. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M (1993) Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82: 1695-1700
40. O'Brien S, Kantarjian H, Estev E, Koller C, Robertson B, Beran M, Andreeff M, Pierce S, Keating M (1994) Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 330: 319-322
41. Orchard JA, Bolam S, Oscier DG (1998) Association of myelodysplastic changes with purine analogues. Br J Haematol 100: 677-679
42. Österborg A, Fassas AS, Anagnostopoulos A, Dyer MJS, Catovsky D, Mellstedt H (1996) Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 93: 151-153
43. Österborg A, Dyer MJS, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H, for the European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 15: 1567-1574
44. Paulus U, Schmitz N, Viehmann K, von Neuhoff N, Dreger P (1997) Combined positive/negative selection for highly effective purging of PBPC grafts: towards clinical application in patients with B-CLL. Bone Marrow Transplant 20: 415-420
45. Pavletic Z, Bierman P, Vose J, Bishop M, Wu D, Pierson J, Kollath J, Kessinger A, Armitage J (1997) Long term outcome of autologous stem cell transplantation for chronic lymphocytic leukemia or small lymphocytic lymphoma (B-CLL). Blood 90: 234a (Abstr)
46. Provan D, Bartlett-Pandite L, Zwicky C, Neuberg D, Maddocks A, Corradini P, Soiffer R, Ritz J, Nadler LM, Gribben JG (1996) Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 88: 2228-2235
47. Rabinowe SN, Soiffer RJ, Gribben JG, Daley H, Freedman AS, Daley J, Pesek K, Neuberg D, Pinkus G, Leavitt PR, Spector NA, Grossbard ML, Anderson K, Robertson MJ, Mauch P, Chayt-Marcus K, Ritz J, Nadler LM (1993) Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 82: 1366-1376
48. Rai KR, Peterson B, Elias L, Shepherd L, Hines J, Nelson D, Cheson B, Kolitz J, Schiffer CA (1996) A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI-C and ECOG Inter-Group Study. Blood 88: 141a (Abstr)
49. Raphael B, Andersen JW, Silber R, Oken M, Moore D, Bennett J, Bonner H, Hahn R, Knospe WH, Mazza J, Glick J (1991) Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: longterm follow-up of an Eastern Cooperative Oncology Group Randomized Clinical Trial. J Clin Oncol 9: 770-776
50. Reinisch W, Willheim M, Hilgarth M, Gasché C, Mader R, Szepfalusi S, Steger G, Berger R, Lechner K, Boltz-Nitulescu G, Schwarzmeier JD (1994) Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. J Clin Oncol 12: 2146-2152
51. Robertson LE, O'Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Keating MJ (1995) Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia 9: 943-945
52. Robertson LE, Garson M, Pugh W, Manning J, Huh Y, Albitar M, Khouri I, Lcrncr S, O'Brien S, Keating M (1994) The 11:14 translocation in chronic lymphocytic leukemia is associated with splenomegaly, advanced disease, and short survival. Blood 84: 457a (Abstr)
53. Rondelli D, Lauria F, Zinzani PL, Raspadori D, Ventura MA, Galieni P, Birtolo S, Forconi F, Algeri R, Tura S (1997) 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders. Eur J Haematol 58: 46-50
54. Rummel M, Schenk M, Renner C, Remhardt U, Knuth A, Hehlmann R, Hoelzer D, Mitrou PS, Bergmann L (1997) Fludarabine and epirubicin in the treatment of CLL as first line therapy or in first relapse. Blood 90: 530a (Abstr)
55. Sarfati M, Chevret S, Chastang C, Biron G, Stryckmans P, Delespessc G, Binet JL, Merle-Beral H, Bron D (1996) Prognostic importance of serum soluble CD23 level in chrome lymphocytic leukemia. Blood 88: 4259-4264
56. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD (1995) 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 13: 570-574
57. Seymour JF, Grigg AP, Szer J, Bardy P, Whitehead S, Fox RM (1997) Fludarabine and mitoxantrone; a highly effective and well-tolerated salvage therapy for low-grade lymphoproliferative disorders. Blood 1997: 343a (Abstr)
58. Shvidel L, Shtarlid M, Klepfish A, Sigler E, Berrebi A (1997) Evans syndrome complicating fludarabine treatment for advanced B-CLL. Br J Haematol 99: 706-713
59. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91: 7556-763
60. Sörensen JM, Vena DA, Fallavollita A, Chun HG, Cheson BD (1997) Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the Group C Protocol Mechanism of the National Cancer Institute: five-year follow-up report. J Clin Oncol 15: 458-465
61. Stilgenbauer S, Döhner K, Bentz M, Lichter P, Döhner H (1998) Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia. Ann Hematol 76: 101-110
62. Tallman MS, Wollins E, Jain V, Schiller G, Shepherd J, Silver R, Peterson L (1997) Leustatin® in the treatment of patients with previously untreated chronic lymphocytic leukemia. Blood 90: 578a (Abstr)
63. Tallman MS, Hakimian D, Zanzig C, Hogan DK, Rademaker A, Rose E, Variakojis D (1995) Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 13: 983-988
64. Tedeschi A, Montillo M, Pagnucco G, Capelli D, Crugnola M, Muti G, Annunziata M, Orlandi E, Ferrara F, Lazzarino M, Leoni P, Moora E (1997) Autoimmune complications in indolent lymphoproliferative disorders treated with fludarabine. Blood 90: 345a (Abstr)
65. Tertian G, Cartron J, Bayle C, Rudent A, Lambert T, Tchernia G (1996) Fatal intravascular autoimmune hemolytic anemia after fludarabine treatment for chronic lymphocytic leukemia. Hematol Cell Ther 38: 359-360
66. Tsiara St, Christou L, Konstantinidou P, Panteli A, Briasoulis E, Bourantas KL (1997) Severe autoimmune hemolytic anemia following fludarabine therapy in a patient with chronic lymphocytic leukemia. Am J Hematol 54: 342
67. Weiss RB, Freiman J, Kweder SL, Diehl LF, Byrd JC (1998) Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 16: 1885-1889
68. Woodcock BE (1993) Cytopenia and fludarabine. Lancet 342: 1049-1050
69. Zinzani PL, Bendandi M, Magagnoli M, Rondelli D, de Vivo A, Benni M, Zamagni E, Cavo M, Tura S (1997) Results of a fludarabine induction and alpha-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. Eur J Haematol 59: 82-88